Overall Perfomance for "Broad Street Alerts"
The following three charts can be used by potential investors to gauge the performance of "Broad Street Alerts":
0 out of 1 campaigns closed down on first day
1 out of 1 campaigns closed up on first day
0 out of 1 campaigns had no net effect
ATNM Promotional Newsletter
The following is a newsletter released by "Broad Street Alerts" promoting Actinium Pharmaceuticals, Inc.
Potential catalyst on the horizon...
Actinium ATNM Awarded Grant by NIH
Good day everyone,
We are continuing our coverage of, Actinium Pharmaceuticals, Inc. NYSE ATNM, a clinical stage biopharmaceutical company.
Current price $11.78 per share
Actinium shares opened at $11.17 per share on Wednesday, October 21, 2020, and quickly gained 8.5% to $12.12share.
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
The NIH has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center MSK to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. Memorial Sloan Kettering Cancer Center is a leader in cellular therapies to treat cancer.
For those of you who wish to read more about the science of the pending study, weve included the link below
Earlier we talked about ATNM trailing other companies, similar in scope, outpacing Actinium in market capitalization by a factor of 3-4X. The new NIH study validates even further the reasons ATNM should have a market cap on par with their peers.
Consider the ATMN recent and near-term potential catalysts
A new research facility focused on developing novel Antibody Radiation Conjugate ARC candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations.
The new NIH grant in collaboration with Memorial Sloan Kettering Cancer Center.
Progress in their clinical trials. Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant. The clinical trial has passed 50% enrollment and updated interim analysis from the study is anticipated soon Q4.
Announcement of a multicenter, open label Phase 12 trial of Actimab-A.
All the milestones listed above have occurred just in the past month. Combined with all the previous activity reported at ATNM, these new steps seem to indicate the company is transitioning into a much larger scale biopharma company.
The ATNM technology is currently directed at indications that cost the worldwide healthcare systems billions of dollars. Even with billions being spent to treat these patients, the outcome is too often lacking good results. ATNMs technology aims to increase the success rate for those indications.
The company shares remain significantly below their recent July high of $19.47 per share.
For those of you new to Actinium this is the process simply condensed
Antibody Radiation-Conjugates ARC combine the targeting ability of antibodies with the cell killing ability of radiation. The ATNM pipeline consists of ARCs targeted toward hematologic blood cancer indications.
Actinium's Antibody Warhead Enabling AWE platform. The power of this technology lies in its alpha emitting payload actinium-225. It emits a powerful dose of high energy but only over a very short distance - about the distance of a few cells or less than the thickness of a piece of paper. This focuses the radiation on the cancer cells and limits exposure to normal tissues.
The short, and overly simplistic explanation of the ATNM technology is that the ARCs seek out specific cancer and other specified cells and attach to them, allowing for a dose of actinium-225 radiation to destroy them.
The ATNM process is currently being evaluated in multiple blood cancer indications.
original report below
Update 102120 1033 AM EST- ATNM opened at $11.17 and has crossed $12.02 today for 7.5% in gains so far and building momentum
Actinium issued news this morning, more on this in our full report coming soon.
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy -
Actinium ATNM is Advancing Twelve Products
Actinium has eight products currently in clinical trials.
Good day everyone,
Today we are revisiting a stock weve covered in the past, Actinium Pharmaceuticals, Inc. NYSE ATNM, a clinical stage biopharmaceutical company.
Current price $10.95 per share
Outstanding shares est. 13.59 million
Float est. 12.34 million shares
Considerations for ATNM shares
Twelve products in development.
Potential near-term catalyst.
Tiny share structure.
Breakout chart set-up.
The companys lead product, Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer Jeff Bridges just announced he has this cells, B cells and stem cells.
Iomab-B is currently being studied in a Phase 3 trial, a 150-patient, randomized controlled clinical trial in patients with relapsed or refractory acute myeloid leukemia AML who are age 55 and above.
In a Phase 2 clinical study in 58 patients with advanced AML or high-risk myelodysplastic syndrome MDS age 50 and older, Iomab-B produced complete remissions in 100% of patients.
Additionally, ATNM has two products in phase 2 clinical trials, five products in phase 1 trials and four pre-clinical products. We included a link below if you want more information on Actinium clinical trial progress and product development
ATNM is gaining investor interest. Institutional investors now have a 13.9% stake in the company. We believe the institutions recognize that ATNM shares could be trading at a discount to their biopharma competition. ATNM has a current market cap of $150M. Lets look at some developmental biopharma companies, similar in scope to Actinium, to see how their market caps compare
XBiotech XBIT $548M
Atreca BCEL $525M
Applied Therapeutics APLT $485M
Odonate Therapeutics ODT $599M
Marinus Pharma MRNS $445M
Viking Therapeutics VKTX $408M
Actinium announced last week, the launch of its new research and development lab facility in New York City. This new research facility expands Actinium's internal RD capabilities and will be focused on developing novel Antibody Radiation Conjugate ARC candidates, ARC therapeutic combination strategies, and supporting AWE platform research collaborations.
The new research facility is exciting news for ATNM and its stakeholders. Weve included a link below to the full press release by the company
Actinium's Antibody Warhead Enabling AWE platform, used for the delivery of the company products to cancer cells, may be a vertical for the company as well as its therapeutic products. The power of this technology lies in its alpha emitting payload actinium-225. It emits a powerful dose of high energy but only over a very short distance - about the distance of a few cells or less. This focuses the radiation on the cancer cells and limits exposure to normal tissues.
Actinium ended Q2 indicating it had $53M in cash. Capital expenditures aside, that cash runway could cover their cash burn for more than a year.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actiniums lead application for our ARCs is targeted conditioning, which is intended to selectively kill patients cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T, and other cell therapies.
ATNM shares are trading 40% off their recent high of $19.47 established on July 27, 2020.
As the chart below indicates, ATNM shares have crossed their 50 DMA and 200 DMA of $9.48 and $8.75 respectively, in a bullish manner. ATNM shares are also leading their 20, 50, and 200 SMAs indicating a potential positive trend.
Full updated report coming soon,
Do we disclose any information to outside parties
We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect
We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.
When registering on our site, as appropriate, you may be asked to enter your e-mail address
What do we use your information for
When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, andor other requests or questions.
How do we protect your information
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
This websitenewsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reportsreleases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our emailblog list as well as any social networking platforms we may use.
PLEASE NOTE WELL SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury monetary or otherwise that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions quote may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. SCS LLC has been compensated twenty three thousand three hundred and thirty three dollars cash via bank wire on 101320 by venado media for this week and continuing coverage over the next 30 days of atnm.The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Copyright 2020 Broad Street Alerts,
Last 1 Stock Promotions By "Broad Street Alerts"
|JETR||Star Jets International, Inc.||September 24, 2020||0.140||59%|